RT Journal Article
T1 Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.
A1 Gallego-Duran, Rocio
A1 Montero-Vallejo, Rocio
A1 Maya-Miles, Douglas
A1 Lucena, Ana
A1 Martin, Franz
A1 Ampuero, Javier
A1 Romero-Gomez, Manuel
K1 NAFLD
K1 NASH
K1 biomarkers
K1 fibrosis
K1 immunology
AB Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has displaced viral hepatitis as the main cause of severe forms of hepatic diseases, although the onset and transition of MAFLD stages still remains unclear. Nevertheless, innate and adaptive immune responses seem to play an essential role in the establishment and further progression of this disease. The immune system is responsible of safeguard and preserves organs and systems function, and might be altered under different stimuli. Thus, the liver suffers from metabolic and immune changes leading to different injuries and loss of function. It has been stablished that cell-cell crosstalk is a key process in the hepatic homeostasis maintenance. There is mounting evidence suggesting that MAFLD pathogenesis is determined by a complex interaction of environmental, genetic and host factors that leads to a full plethora of outcomes. Therefore, herein we will revisit and discuss the interplay between immune mechanisms and MAFLD, highlighting the potential role of immunological markers in an attempt to clarify its relationship.
PB Frontiers Research Foundation
YR 2021
FD 2021-11-24
LK https://hdl.handle.net/10668/28371
UL https://hdl.handle.net/10668/28371
LA en
NO Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, et al. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol. 2021 Nov 24;12:667354.
DS RISalud
RD Apr 7, 2025